期刊
CANCER DISCOVERY
卷 6, 期 6, 页码 584-593出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-16-0062
关键词
-
类别
资金
- National Cancer Institute (Lung SPORE) [P50CA70907]
- NIH [C06 RR30414]
- Southland Financial Foundation
- [RO1 AG001228]
Telomeres progressively shorten throughout life. A hallmark of advanced malignancies is the ability for continuous cell divisions that almost universally correlates with the stabilization of telomere length by the reactivation of telomerase. The repression of telomerase and shorter telomeres in humans may have evolved, in part, as an anticancer protection mechanism. Although there is still much we do not understand about the regulation of telomerase, it remains a very attractive and novel target for cancer therapeutics. This review focuses on the current state of advances in the telomerase area, identifies outstanding questions, and addresses areas and methods that need refinement. Significance: Despite many recent advances, telomerase remains a challenging target for cancer therapy. There are few telomerase-directed therapies, and many of the assays used to measure telomeres and telomerase have serious limitations. This review provides an overview of the current state of the field and how recent advances could affect future research and treatment approaches. (C) 2016 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据